GSK's long-acting HIV injection endorsed by EU panel
Oct 16 (Reuters) - GlaxoSmithKline Plc GSK.L said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's JNJ.N rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.
The treatment is a long-acting regimen, which can reduce the number of doses required to 12 or six per year instead of a daily intake of pills.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Ramakrishnan M.)
((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.